Tessera Therapeutics

Tessera Therapeutics is an early‑stage life sciences company and a Flagship Pioneering venture developing Gene Writing™, a platform technology that programs engineered proteins to write RNA templates into the genome. The approach is designed to install, replace, or remove DNA sequences—enabling potentially durable, one‑time genetic medicines for inherited and other diseases. Tessera combines proprietary molecular engineering and delivery efforts to build a pipeline of therapeutic programs and partnerships aimed at translating the Gene Writing platform into clinical treatments.